News & Events

Prof. Gabby Sarusi Develops One Minute Coronavirus Test

13 May 2020
BEER-SHEVA, Israel, May 13, 2020 – Ben-Gurion University of the Negev's Prof. Gabby Sarusi has developed and is now validating a test that identifies carriers of the COVID-19 virus in less than a minute with greater than 90% accuracy and at a dramatically lower price than any other method available

NEOVII to develop a novel vaccine for Covid -19 in an exclusive partnershipa with RAMOT@TAU

12 May 2020
Rapperswil, Switzerland, Tel Aviv, Israel, May 12, 2020, Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor Jonathan Gershoni of the School of Molecular Cell Biology and Biotechnology to develop a novel and potentially life-saving COVID-19 vaccine.

BGU Scientists Develop Anti-Coronavirus Surface Coating Based on Nanomaterials

05 May 2020
Prof. Angel Porgador, from the Department of Microbiology, Immunology and Genetics at Ben-Gurion University (BGU) and the National Institute of Biotechnology in the Negev (NIBN), and Dr. Mark Schvartzman, the Department of Materials Engineering at BGU, are developing novel surface coatings that will have a long term effect, and contain nanoparticles of safe metal ions and polymers
with anti-viral and anti-microbial activity.

Jerusalem researchers say they’ve developed injection to fight superbugs

05 May 2020
One scientist asserts new treatment, which allows previously topical drug to be administered intravenously, is ‘a game-changer’ in the battle against antibiotic-resistant bacteria.

Stem cells provide Covid-19 relief

04 May 2020
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D studies, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science.

Brain-saving technology New device combines algorithms, infrared light, and imaging to monitor bleeding in the brain

23 April 2020
Imagine a physician peering into a patient’s head—from miles away—and diagnosing impending brain damage from an expanding blood clot, by simply glancing at a mobile device

MigVax raises $12M for its COVID-19 vaccine efforts

22 April 2020
Worldwide, there are numerous efforts underway to create a vaccine for COVID-19. MigVax, an Israeli startup that’s affiliated with the Migal Galilee Research Institute, thinks it can speed up this process by quite a bit, in part, because it had already worked on building a framework for the Infectious Bronchitis Virus, a coronavirus that infects chickens, and that has proven to be safe in animals.

RAMOT@TAU awarded U.S. patent for novel coronavirus vaccine design

19 April 2020
The patent covers a vaccine that targets the most vulnerable point in a coronavirus’s structure, through which it penetrates human cells. The patent has been submitted by Ramot, the technology transfer company of Tel-Aviv University and was granted in March by the U.S. patent and trademark office.

Innocan Pharma collaborates with RAMOT@TAU to develop a new revolutionary approach to treat the Covid -19 Corona Virus with exosomes-loaded CBD

17 April 2020
Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 17, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has entered into a sponsored research agreement dated April 17, 2020 (the "Research Agreement") with Ramot at Tel Aviv University ("Ramot") to collaborate with Tel Aviv university to develop a novel, revolutionary approach to treat COVID-19 by using Cannabidiol (CBD) loaded Exosomes ("ICLX").

Cancer treatment co Kahr Medical raises $18m

26 February 2020
Cancer treatment co Kahr Medical raises $18m - Jerusalem-based cancer treatment startup Kahr Medical Ltd. has raised $18 million. The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings (HBL), Pavilion Capital, and Mirae Asset Venture.